A5041581571- Schizophrenia research and treatment
- Mental Health and Psychiatry
- Electroconvulsive Therapy Studies
- Mental Health Treatment and Access
- Bipolar Disorder and Treatment
- Mental Health and Patient Involvement
- Diet and metabolism studies
- Health Policy Implementation Science
- Hepatitis C virus research
- Transcranial Magnetic Stimulation Studies
- Epilepsy research and treatment
- Tryptophan and brain disorders
- Psychosomatic Disorders and Their Treatments
- Alcoholism and Thiamine Deficiency
- Healthcare Policy and Management
- Neurological disorders and treatments
- Primary Care and Health Outcomes
- Treatment of Major Depression
- Obsessive-Compulsive Spectrum Disorders
- Neurological and metabolic disorders
- Ion Transport and Channel Regulation
- Educational Research and Science Teaching
- Glycogen Storage Diseases and Myoclonus
- Pharmacology and Obesity Treatment
- Healthcare innovation and challenges
University of Washington
2024
Columbia University Irving Medical Center
2024
Northwestern University
2016-2024
University of Utah
2024
Northwestern University
2021
Northwestern Medicine
2021
Milliman (United States)
2019
University of Minnesota
2019
Institute of Behavioral Sciences
2007-2017
Rush University Medical Center
2007-2016
Article AbstractBackground: Transcranial magnetic stimulation (TMS) has demonstrated efficacy in the treatment of major depressive disorder; however, prior studies have provided only partial safety information. We examined acute TMS a randomized sham-controlled trial, under open-label conditions, and its durability benefit. Method: Aggregate data were obtained from comprehensive clinical development program examining use disorder. There 3 separate protocols, including 325 patients 23 sites...
Prior randomized clinical trials have reported benefit of fluvoxamine ≥200 mg/d vs placebo for patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
This 24-week pilot study assessed the efficacy, tolerability, and safety of adjunctive metformin versus placebo for prevention olanzapine-associated weight gain in community-dwelling adult patients with schizophrenia, schizoaffective disorder, bipolar or major depression psychotic features.In a double-blind study, 25 were randomly assigned to receive 24 weeks either olanzapine plus placebo. Metformin extended release was titrated 2000 mg daily as tolerated. No other antipsychotics allowed,...
Introduction: Bipolar disorder is characterized by mood instability, which can be challenging to manage. First-line pharmacological approaches usually involve lithium, anticonvulsants and antipsychotics. Over the past fifteen years, several second-generation antipsychotics have demonstrated benefits for various phases of this disorder. Areas covered: This article examines pharmacodynamics pharmacokinetics quetiapine; its evidence base as an acute maintenance monotherapy or adjunctive therapy...
Background:The Psychiatric Collaborative Care Model (CoCM) is a highly evidence-based model of behavioral health care delivery in primary settings.Rural (RPC) clinics may face unique barriers to implementation CoCM that are important for teams understand.As part multisite RPC clinics, we explored staff and practice facilitator (PF) perspectives on promising strategies implementation.Methods: This study followed sequential explanatory mixed methods design.Clinics (n=23) were each assigned...
There is strong evidence supporting implementation of the Collaborative Care Model within primary care. Fee-for-service payment codes, published by Current Procedural Terminology in 2018, have made collaborative care separately reimbursable for first time. These codes (ie, 99492-99494) reimburse time spent per month any member team engaged Care, including behavioral managers, providers, and consulting psychiatrists. Time-based billing these presents challenges providers delivering...
The Collaborative Care Model (CoCM) is a well-established treatment for depression in primary care settings. critical drivers and specific strategies improving implementation sustainment are largely unknown. Rigorous pragmatic research needed to understand CoCM processes outcomes.This study hybrid Type 2 randomized roll-out effectiveness-implementation trial of 11 practices affiliated with an academic medical center. Behavioral Health Program (CBHP) was developed as means access effective...
Dr. Rado is Assistant Professor of Psychiatry and Internal Medicine, Rush University Medical Center, 2150 West Harrison, Chicago, IL 60612; E-mail: [email protected]. Formerly Frank Ayd's International Drug Therapy Newsletter has disclosed that he is/was the recipient grant/research support from Lilly, Otsuka, Neuronetics a speaker for Lilly. He also use armodafanil, atomoxetine, buspirone, citalopram, electroconvulsive therapy, escitalopram, fluoxetine, galantamine, lamotrigine, memantine,...
Rado, Jeffrey MD; Janicak, Philip G. MDEditor(s): MD, Editor Author Information
Janicak, Philip G. MD; Rado, Jeffrey T. MDEditor(s): MD Author Information
People with chronic mental disorders, such as schizophrenia, experience excessive medical morbidity and mortality. This results from various patient, disease, health-system factors. Among them is inadequate screening for treatment of common conditions. There a growing impetus psychiatrists to play larger role in the physical health their patients. Clinical context, provider comfort competence, patient preference are all factors that must be considered. Psychiatrists' increasing involvement...
Abstract Background The Collaborative Care Model (CoCM) is an evidence-based mental health treatment in primary care. A greater understanding of the determinants successful CoCM implementation, particularly characteristics multi-level implementers, needed. Methods This study was a process evaluation Behavioral Health Program (CBHP) (NCT04321876) which implemented 11 care practices. CBHP implementation included screening for depression and anxiety, referral to CBHP, with behavioral managers...